
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Compass Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

20454B104

(CUSIP Number)

**Commander Aggregator, LP
c/o The Corporation Trust Company, Corporation Trust Cntr, 1209 Orange St.
Wilmington, New Castle, DE, 19801
(302) 658-7581**

**Sophia Hudson, P.C.
601 Lexington Avenue,
New York, NY, 10022
(212) 446-4800**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/14/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 20454B104

1 Name of reporting person
 Commander Aggregator, LP
 Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
 Source of funds (See Instructions)

4 OO
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
 Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With:

8 0.00
 Shared Voting Power

9 7,788,150.00
 Sole Dispositive Power

10 0.00
 Shared Dispositive Power

11 7,788,150.00
 Aggregate amount beneficially owned by each reporting person

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13
 Percent of class represented by amount in Row (11)

14 4.5 %
 Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Percentage of ownership is based upon 171,572,498 shares of common stock, par value \$0.0001 per share ("Common Stock"), issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) ("Prospectus") with the Securities and Exchange Commission ("SEC") on August 13, 2025.

SCHEDULE 13D

CUSIP No. 20454B104

1 Name of reporting person
 Enavate Sciences, LP
 Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 OO
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 8 0.00
Shared Voting Power

9 7,788,150.00
Sole Dispositive Power

10 0.00
Shared Dispositive Power

11 7,788,150.00
Aggregate amount beneficially owned by each reporting person

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13
Percent of class represented by amount in Row (11)

14 4.5 %
Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

SCHEDULE 13D

CUSIP No. 20454B104

1 Name of reporting person
Enavate Sciences GP, LLC
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 OO
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power
	8	0.00
	9	Shared Voting Power
	10	7,788,150.00
	11	Sole Dispositive Power
	12	0.00
	13	Shared Dispositive Power
	14	7,788,150.00
		Aggregate amount beneficially owned by each reporting person
		7,788,150.00
		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
		<input type="checkbox"/>
		Percent of class represented by amount in Row (11)
		4.5 %
		Type of Reporting Person (See Instructions)
		OO

Comment for Type of Reporting Person: Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

SCHEDULE 13D

CUSIP No. 20454B104

1	Name of reporting person
	Enavate Sciences Holdings, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions)
	OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	<input type="checkbox"/>
6	Citizenship or place of organization
	DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power
	8	0.00
	9	Shared Voting Power
	10	7,788,150.00
	11	Sole Dispositive Power
	12	0.00
	13	Shared Dispositive Power

7,788,150.00

Aggregate amount beneficially owned by each reporting person

11

7,788,150.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12



Percent of class represented by amount in Row (11)

13

4.5 %

Type of Reporting Person (See Instructions)

14

OO

Comment for Type of Reporting Person: Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, par value \$0.0001 per share

Name of Issuer:

(b)

Compass Therapeutics, Inc.

Address of Issuer's Principal Executive Offices:

(c)

80 Guest St., Suite 601, Boston, MASSACHUSETTS , 02135.

Item 1 Comment: This Amendment No. 1 ("Amendment No. 1") to Schedule 13D amends and supplements the initial Schedule 13D filed on November 14, 2022 (as so amended, the "Schedule 13D"). Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Schedule 13D as amended from time to time.

Item 5. Interest in Securities of the Issuer

(a) Item 5(a) of this Statement is hereby amended and restated in its entirety as follows: The information set forth in rows (11) and (13) of the cover pages of this Statement is incorporated by reference into this Item 5.

(b) Item 5(b) of this Statement is hereby amended and restated in its entirety as follows: The information set forth in rows (11) and (13) of the cover pages of this Statement is incorporated by reference into this Item 5.

(c) None of the Reporting Entities has effected any transactions in the Common Stock in the past 60 days.

(d) Not Applicable

(e) As a result of the decrease in the outstanding shares, effective as of August 14, 2025, as reported by the Issuer in the Prospectus filed on August 13, 2025, the Reporting Entities' beneficial ownership ceased to exceed 5% on such date and the Reporting Entities are no longer subject to Section 13 reporting.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Commander Aggregator, LP

Signature: /s/ James P. Boylan

Name/Title: James P. Boylan / Chief Executive Officer

Date: 08/18/2025

Enavate Sciences, LP

Signature: /s/ James P. Boylan

Name/Title: James P. Boylan / Chief Executive Officer

Date: 08/18/2025

Enavate Sciences GP, LLC

Signature: /s/ James P. Boylan

Name/Title: James P. Boylan / Chief Executive Officer

Date: 08/18/2025

Enavate Sciences Holdings, LLC

Signature: /s/ James P. Boylan

Name/Title: James P. Boylan / Chief Executive Officer

Date: 08/18/2025

**Comments
accompanying
signature:**

Enavate Sciences, LP By: Enavate Sciences GP, LLC Its: General Partner, Enavate Sciences GP, LLC
By: Enavate Sciences Holdings, LLC Its: Sole Member